AstraZeneca vaccine booster shot efficient in opposition to Omicron
© Reuters. FILE PHOTO: People pose with syringe with needle in front of the displayed AstraZeneca logo in this illustration from December 11, 2021. REUTERS / Dado Ruvic / Illustration
(Reuters) – A three-dose course of the COVID-19 vaccine from AstraZeneca (NASDAQ 🙂 is effective against the Omicron coronavirus variant, the pharmaceutical company said Thursday, citing data from an Oxford University laboratory study.
The study, which had yet to be published in a peer-reviewed medical journal, showed that after the booster, antibody levels to Omicron were higher than those in people who had contracted COVID-19 and had naturally recovered from it.
After taking three doses of the vaccine, neutralizing levels against Omicron were similar to those against the Delta variant of the virus after two doses, the company added.
The Anglo-Swedish drug maker said the Oxford University researchers who conducted the study are independent of those who worked with AstraZeneca on the Vaxzevria vaccine.
Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, which means that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media, or anyone involved in Fusion Media, assumes no liability for any loss or damage arising out of reliance on the information contained on this website, including data, prices, charts, and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.